Market Overview - The Hong Kong stock market opened lower on December 15, with the Hang Seng Index down 1% at 25,718.14 points, the Hang Seng Tech Index down 1.34% at 5,562.67 points, and the State-Owned Enterprises Index down 1.09% at 8,980.13 points [1] - Major tech stocks declined, including Alibaba down 2.14%, Tencent down 1.62%, and JD.com down 0.61% [1] - The innovative drug sector saw several stocks open lower, with Genscript Biotech down 5.92% and Zai Lab down 3.48% [1] - Chinese brokerage stocks collectively fell, with Everbright Securities dropping over 1% [1] - The automotive sector also experienced declines, with Li Auto down over 2% and XPeng down nearly 2% [1] - However, three-child policy concept stocks and photovoltaic stocks mostly rose, with star stock Jinxin Fertility rising about 3% [1] Company News - China Merchants Energy (01138.HK) signed shipbuilding contracts for one ethylene ship and eighteen oil tankers, totaling RMB 7.882 billion [2] - ZhongAn Online (06060.HK) reported cumulative original insurance premium income of approximately RMB 32.904 billion for the first eleven months [3] - R&F Properties (02777.HK) achieved total sales revenue of approximately RMB 12.7 billion in the first eleven months, a year-on-year increase of 24.63% [4] - Yida China (03639.HK) reported contract sales amounting to approximately RMB 681 million in the first eleven months, a year-on-year decrease of 23.22% [5] - Bole Technology (02592.HK) successfully held a meeting after the second phase of clinical trials for CBT-004 [6] - Junshi Biosciences (02696.HK) received acceptance for its marketing application for Hansizhuang® in combination with chemotherapy for gastric cancer [6] - CSPC Pharmaceutical Group (01093.HK) received approval for a new indication for its drug, Donyin® (liposomal irinotecan injection), for first-line treatment in metastatic pancreatic cancer patients [6] - Biyuan (00926.HK) increased its investment in ERX to maintain a 3% stake to support innovative research and development of non-GLP-1 weight loss therapies [7] - Hengrui Medicine (01276) received approval for clinical trials for HRS-1780 tablets [8] - AVIC Industry (02357.HK) plans to acquire a 59.1816% partnership interest in Hangtou Yuhua for a consideration of RMB 202 million [9] - China Environmental Resources (01130.HK) intends to acquire 90% equity in Sichuan Yuanlai Shun Recycling Resources Co., Ltd. for RMB 9 million [10] - AVIC Industry (02357.HK) proposed to implement full circulation of H-shares [11] - Yabo Technology Holdings (08279.HK) signed a framework agreement with Alipay (Hangzhou) [12] Institutional Insights - Guosen Securities indicated that the short-term adjustment in the Hong Kong stock market opens up space for a market rise in 2026, with net inflows from southbound funds exceeding RMB 110 billion in November [13] - CITIC Securities noted strong performance in gold and silver, while other risk assets were weak, predicting a segmented market for precious metals in 2025 [13] - CITIC Securities also emphasized the importance of resource self-sufficiency in the lithium industry, highlighting the need for low-cost quality resources to navigate market cycles [14]

文/二马小姐 快要跨年了，港股经过一轮比较像样的调整，有点蠢蠢欲动。此刻，不妨再度探讨下港股的抄底思路。 最近也写过多次港股，一直看好这个市场。上个月去一趟香港，距离上一次去大概也就几个月。发现中 环的酒店比早前涨价不少。和朋友提前约午饭，没想到餐厅居然早早位子订满了，换了几家才订上位 子。我们开玩笑说，可能今年港股热闹，各种IPO都在奔赴香港。 虽然港股最近调整，幅度不小，但这其实是港股一贯的风格。如果观察港股足够久，就知道，这个离岸 市场的大波段是相当明显的。涨的时候一波非常快，随后需要调整一阵子。对港股玩家来说，通常要提 前埋伏，而不是大幅上涨后才去追高，这是港股的第一铁律！ 比如今年，港股有两个大波段。以恒生科技指数为例，第一次从1月开始涨到3月。调整之后，从四月开 始第二波上涨，一直到10月初。实际上，去年港股比A股回暖也更早一些。 图：恒生科技指数走势 另一个视角，从流动性，以及海外市场的冲击看，随着美联储降息的靴子落地，情况基本上也比较明朗 了。美股关于AI泡沫的担忧，此前也释放了一定的风险。本周还有关于日本是否加息的决定，也将靴 子落地。 总而言之，这个时候，应该可以来探讨下港股的抄底思路了。 ...

Core Insights - The report indicates that in 2024, there are 816 potential unicorn companies in China, with 255 new entrants, over 90% of which are in cutting-edge technology sectors [1][2] - The report is the sixth edition published by the Great Wall Enterprise Strategic Research Institute, which has been releasing unicorn-related reports for nine consecutive years [1] Group 1: Potential Unicorn Companies - The number of potential unicorn companies has increased from 296 in 2019 to 816 in 2024, representing an approximate growth of 1.8 times [2] - Among the potential unicorns, 547 companies (67%) were established within the last five years and valued at $100 million, while 269 companies (33%) were founded 5-9 years ago and valued at $500 million [1] - In 2024, 747 potential unicorn companies belong to the cutting-edge technology sector, with 363 deriving their technology from universities and research institutions [2] Group 2: Industry Distribution - Potential unicorn companies are distributed across 42 sectors, with over 100 companies in the chip and innovative drug sectors, followed by 78 in new semiconductors and 52 in clean energy [2] - New entrants are found in 31 sectors, with more than 20 new companies in chip, new semiconductor, innovative drug, and power battery sectors, and over 50% of new companies in smart flight, smart hardware, power batteries, new materials, and synthetic biology sectors [2] - The proportion of potential unicorn companies in cutting-edge technology has increased from 56.4% in 2019 to 91.5% in 2024 [2]

Group 1 - The central economic work conference has set the tone for 2026 economic work, with expectations for a "cross-year market" and "spring excitement" rising among broker reports [1] - The policy focus on "expanding domestic demand and countering involution" is expected to lead the market out of deflation, with technology sectors like AI computing power and commercial aerospace being key offensive directions [1][4] - There is a growing preference for low-volatility, high-dividend assets, indicating a potential market style switch [1][3] Group 2 - Citic Securities suggests seeking intersection in configurations, focusing on products with overseas exposure and positive changes in domestic demand as catalysts [2] - The report emphasizes that while external demand products have been validated, the potential for exceeding expectations is limited, and investors' low expectations could lead to valuation elasticity if domestic demand surprises positively [2] - The focus remains on industries where China has a global share advantage, such as non-ferrous metals, chemicals, and new energy, with an emphasis on companies that can enhance global pricing power [3] Group 3 - The market is expected to enter a new phase of recovery, with significant support from previous price levels and a shift in investor sentiment following recent adjustments [5] - Structural risks are emerging, which could hinder the sustained strength of advantageous themes, as indicated by high transaction concentration [5][6] - The focus on low-volatility and stable return assets is increasing, with potential interest in service consumption sectors like aviation, duty-free, and hotels [3][12] Group 4 - The central economic work conference has highlighted the importance of expanding domestic demand and addressing involution, clarifying the path out of deflation [7][19] - The emphasis on enhancing the income of middle and low-income groups and stimulating private investment indicates a shift towards endogenous growth drivers [7] - The conference also pointed out the need for a unified national market and the deepening of anti-involution measures, which are crucial for the recovery of corporate profits and subsequent improvements in resident income [8] Group 5 - The new policy deployment is expected to support the A-share market's cross-year performance, with a focus on TMT and advanced manufacturing sectors [9] - The historical performance of the A-share market during the start of the "13th Five-Year" and "14th Five-Year" plans suggests a positive outlook for 2026 [9] - The report indicates that the market may experience fluctuations due to various domestic and international events, but the overall economic policy is expected to remain supportive [9] Group 6 - The AI industry is characterized by a competition in full-stack capabilities and deep penetration into various application scenarios [10][11] - Domestic firms are focusing on building a full-stack system in the computing hardware sector, with significant advancements in AI solutions and infrastructure [11] - The demand for AI infrastructure is expected to drive growth in related sectors, including telecommunications and high-spec data centers [11][16] Group 7 - The commercial aerospace sector is entering a period of heightened activity, supported by new policies and government initiatives [17] - The establishment of a national commercial aerospace development fund aims to attract private investment and enhance the capabilities of commercial companies [17] - Recent advancements in satellite internet and frequent launches are expected to benefit the entire aerospace industry chain [17]

Group 1 - Multiple pharmaceutical stocks announced positive news, including Jiuan Medical's FDA pre-market notification for home test kits for influenza and COVID-19, allowing normal sales in the U.S. market [1] - Junshi Bioscience received FDA approval for clinical trials of its EGFR/HER3 bispecific antibody drug for treating advanced solid tumors [1] - Innovent Biologics' BTK inhibitor, Orelabrutinib, reached primary endpoints in a Phase II trial for systemic lupus erythematosus and has been approved for Phase III trials [2] Group 2 - The Chinese innovative drug industry is at a critical turning point, with over $100 billion in licensing deals in the first three quarters of 2025, indicating significant potential for domestic innovative drugs [3] - Major collaborations between Chinese companies and multinational corporations include a $12 billion deal between Hengrui and GSK, and a $114 billion potential deal between Innovent and Takeda [3] - The Chinese innovative drug sector is expected to show a compound annual growth rate of 20.2% from 2024 to 2028, with the market size projected to reach 26.9 billion yuan by 2028 [1][4] Group 3 - The pharmaceutical industry is anticipated to thrive by 2025, with the Hang Seng Index expected to double in value [4] - The innovative drug sector's listed companies achieved a total revenue of 48.83 billion yuan in the first three quarters of 2025, a 22% year-on-year increase, marking the first quarterly profit since inception [4] - The investment landscape is shifting from a focus on academic backgrounds and preclinical data to a stronger emphasis on companies' tangible strengths and product quality [4]

Core Insights - Multiple pharmaceutical companies have recently announced positive developments, indicating a potential growth phase in the industry [1][2][4]. Group 1: Company Announcements - Jiuan Medical's U.S. subsidiary received pre-market notification from the FDA for its home testing kits for multiple viruses, including COVID-19, allowing for normal sales in the U.S. market [1]. - Junshi Bioscience's dual-specific antibody drug for treating advanced solid tumors has received FDA approval for clinical trials [1]. - Innovent Biologics announced that its BTK inhibitor, Orelabrutinib, has met primary endpoints in a Phase II study for systemic lupus erythematosus and has been approved for Phase III trials [1]. - Yipinhong's Qinxiang Qingjie oral solution has been approved as a national secondary protected traditional Chinese medicine, and the company is set to receive up to $15 billion (approximately 67.13 billion RMB) from Sobi for a new URAT1 inhibitor [2]. Group 2: Market Trends - The Chinese innovative drug sector is experiencing a significant turnaround after a challenging period from 2021 to 2024, with total external licensing amounts surpassing $100 billion in the first three quarters of 2025 [4]. - Major collaborations between Chinese innovative drug companies and multinational corporations (MNCs) are on the rise, exemplified by significant deals such as the $12 billion partnership between Hengrui Medicine and GSK [4]. - The speed and cost-effectiveness of Chinese drug development are becoming competitive advantages, with drug discovery processes being 2-3 times faster than international counterparts [4]. Group 3: Financial Performance - The innovative drug sector in China reported a total revenue of 48.83 billion RMB in the first three quarters of 2025, reflecting a year-on-year growth of 22% [5]. - The sector achieved its first quarterly profit since its inception, with a net profit of 1.1 billion RMB in the third quarter [5]. Group 4: Investment Landscape - The capital market for Chinese innovative drugs is undergoing a transformation, shifting from a focus on academic backgrounds and preclinical data to a stronger emphasis on tangible product capabilities [6].

在盈利视角下，在"反内卷"政策推动下，PPI有望持续回升，企业盈利也将不断修复。综合当前市场预 期，2026年全A非金融归母净利润同比增速预计在10%至14%。在估值端，2026年A股具备较大提升潜 力，叠加流动性宽松及潜在的财政扩张预期，市场整体空间依然乐观。 2025年微观层面的流动性改善为股市注入了重要动能，这一逻辑在2026年的重要性依旧，但资金结构或 将出现变化： 2026年作为"十五五"规划开局之年，产业领域潜在催化因素丰富，流动性重要增量有望来自居民存款搬 家。我们认为，伴随PPI回升，企业盈利将持续修复，A股牛市格局有望延续，市场估值仍具备可观的 提升空间。节奏层面，当前可积极布局以应对可能前置的春季躁动，从中期维度来看，明年上半年将是 较好的行情窗口。 2025年，A股走势大致可划分为两个阶段，核心逻辑均为科技产业引领，叠加政策端与流动性的共振， 其中7至9月居民存款搬家与杠杆资金注入共同推动市场走出一轮主升浪。2026年，产业催化将持续增 多，新质生产力领域"DeepSeek时刻"有望持续涌现，新兴产业景气度将延续，与此同时货币宽松环境大 概率维持，增量流动性值得期待。 从当前存款市场格局 ...

Group 1 - The report highlights that 2025 will be a breakthrough year for the interaction between China's technology and capital markets, with a structural bull market emerging in the technology sector [3] - The A-share market is expected to surpass 4000 points, driven by a strong focus on technology and a wide range of capital interest in the tech field [3][4] - The semiconductor industry is identified as the core engine of the current "technology bull," with revenue reaching 479.38 billion yuan and a net profit increase of 52.98% year-on-year in the first three quarters of 2025 [4] Group 2 - Investment logic in the artificial intelligence sector is shifting from "imagination premium" to "realization and monetization capability," with approximately 709 AI investment events recorded in the first 11 months of 2025, a 136% increase compared to the entire year of 2024 [5] - The innovative drug sector is experiencing significant growth, with the Hong Kong innovative drug index soaring over 100%, and eight companies in A-share and Hong Kong reaching a market value of over 100 billion yuan [5] - The report emphasizes the importance of a high-level cycle between technology and capital, with artificial intelligence technology being a potential driving force for the next technological revolution [5][6]

Group 1 - The core viewpoint is that "technological innovation + anti-involution" will be the two main investment themes for 2026, with expectations of a bullish A-share market driven by improving corporate profits and liquidity from resident deposit migration [2][4] - The A-share market is anticipated to experience a significant increase in non-financial net profit growth, projected at 10% to 14% year-on-year for 2026, supported by a recovering Producer Price Index (PPI) and favorable liquidity conditions [2][3] - The liquidity structure is expected to change, with a notable increase in the proportion of A-share financing balance to circulating market value, which is currently at 2.58%, indicating a potential for further market growth [3] Group 2 - The investment focus for 2026 will lean towards growth sectors, particularly in technology and new energy, as the "14th Five-Year Plan" emphasizes technological advancement and economic transformation [4] - Key investment opportunities will include sectors with price increase expectations and cyclical benefits, such as industrial metals, basic chemicals, robotics, and innovative pharmaceuticals, driven by policy and demand recovery [4] - The market is expected to stabilize with reduced volatility, supported by regulatory measures encouraging long-term capital investment and the maturation of high-interest deposit products [3]

Group 1 - The central economic work conference emphasizes expanding domestic circulation as a key focus, similar to last year, but with significant differences in expectations and pricing for domestic and foreign demand stocks [1][12] - There is a strong performance expectation for overseas exposure stocks, but the difficulty in further valuation increases is acknowledged; meanwhile, domestic demand stocks have potential for significant valuation elasticity if they exceed expectations [1][12] - The market is currently viewed as an important window for positioning in the spring market, with expectations for large-cap growth driven by industry trends and benefiting from insurance capital allocations [2][13] Group 2 - The market is expected to enter a new wave of trends as the underlying logic of the bull market remains intact, driven by structural trends and capital market reforms [3][14] - A-shares are still in an upward channel, with a transition from policy-driven momentum to profit-driven momentum anticipated, supported by recovering prices and domestic demand [4][15] - The upcoming policies are expected to create a favorable environment for risk assets, with a focus on sectors such as artificial intelligence, new energy, and consumer services [5][16] Group 3 - The cross-year market is likely to see a rotation of sectors, with a focus on technology and advanced manufacturing, while defensive and consumer sectors may also be considered in the short term [7][17] - The economic gears are expected to continue moving forward despite fluctuations in market expectations, with a focus on fundamental changes rather than price volatility [8][18] - The market structure is anticipated to evolve from a tech-dominated landscape to a more balanced bull market across various sectors, driven by policy support for growth and structural transformation [6][19]